Uncategorized
Trefoil Therapeutics secures $5.2 million in financing
Trefoil Therapeutics has raised $5.2 million in Series 1 financing, led by Hatteras Venture Partners, according to a company press release. The funding, along with a collaborative research agreement with the National Institutes of Health National Center for Advancing Translational Sciences Therapeutics for Rare and Neglected Diseases, will go toward research to support an investigational new drug filing for TTHX1114, the release said.